Literature DB >> 16782042

Anti-HIV drugs and the mitochondria.

Marcello Pinti1, Paolo Salomoni, Andrea Cossarizza.   

Abstract

Several drugs are currently used that can significantly prolong the course of the infection with the human immunodeficiency virus (HIV), the cause of the acquired immunodeficiency syndrome (AIDS). Among these drugs, the nucleosidic inhibitors of viral reverse transcriptase can alter mitochondrial (mt) function by inhibiting the mitochondrial DNA polymerase gamma (the enzyme responsible for the replication of mtDNA). Decreased mtDNA content provokes a diminished synthesis of respiratory chain enzymes, leading to alterations in mt function. These are in turn responsible for a variety of side effects frequently observed in HIV+ patients, that range from hyperlactatemia and lactic acidosis to lipodystrophy, a pathology characterized by accumulation of visceral fat, breast adiposity, cervical fat-pads, hyperlipidemia, insulin resistance and fat wasting in face and limbs. In this paper, data concerning the effects of different compounds on mitochondria, their role in the pathogenesis of lipodystrophy, and problems related to studies on the mt toxicity of antiviral drugs are reviewed and thoroughly discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782042     DOI: 10.1016/j.bbabio.2006.05.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  33 in total

Review 1.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

2.  Metabolic syndrome in relation to cardiorespiratory fitness, active and sedentary behavior in HIV+ Hispanics with and without lipodystrophy.

Authors:  Farah A Ramírez-Marrero; Jorge L Santana-Bagur; Michael J Joyner; Jorge Rodríguez-Zayas; Walter Frontera
Journal:  P R Health Sci J       Date:  2014-12       Impact factor: 0.705

Review 3.  Viral product trafficking to mitochondria, mechanisms and roles in pathogenesis.

Authors:  Chad D Williamson; Roberta L DeBiasi; Anamaris M Colberg-Poley
Journal:  Infect Disord Drug Targets       Date:  2012-02

Review 4.  Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients.

Authors:  Carlos G Musso; Waldo H Belloso; Richard J Glassock
Journal:  World J Nephrol       Date:  2016-01-06

Review 5.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

6.  Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry.

Authors:  Andrea Cossarizza; Roberta Ferraresi; Leonarda Troiano; Erika Roat; Lara Gibellini; Linda Bertoncelli; Milena Nasi; Marcello Pinti
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 7.  Ageing and inflammation in patients with HIV infection.

Authors:  M Nasi; S De Biasi; L Gibellini; E Bianchini; S Pecorini; V Bacca; G Guaraldi; C Mussini; M Pinti; A Cossarizza
Journal:  Clin Exp Immunol       Date:  2016-08-09       Impact factor: 4.330

8.  Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion.

Authors:  Metodi V Stankov; Reinhold E Schmidt; Georg M N Behrens
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

Review 9.  The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction.

Authors:  Erik R Kline; Roy L Sutliff
Journal:  J Investig Med       Date:  2008-06       Impact factor: 2.895

Review 10.  Efavirenz: a decade of clinical experience in the treatment of HIV.

Authors:  Franco Maggiolo
Journal:  J Antimicrob Chemother       Date:  2009-09-18       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.